Description
Patients with HIV have decreased mortality with new and effective antiretroviral therapy. We are increasingly seeing patients with HIV and dyslipidaemia and there are still many unanswered questions regarding cardiovascular risk assessment and management of patients with HIV associated dyslipidaemia. This article hopes to simplify and present what is currently known on the subject.
